|
 |
European Pharmaceutical Contractor
|
Welcome to the latest edition of EPC - winter seems to have appeared very suddenly!
I am pleased that we have a keynote article in this issue from Trevor Jones of the Association of the British Pharmaceutical Industry, in which he highlights issues of importance to the whole industry. The article considers the World Trade Organization's deal concerning the provision of generic drugs in less developed areas of the world. He highlights how industry works in partnership with public organisations to find ways to treat diseases in those areas. He also emphasises that it is not just the provision of treatments which is important - there needs to be an adequate infrastructure to ensure that diseases are efficiently diagnosed and then treated.
Partnerships designed to solve health problems are also identified in an article from John Savopoulos of Datamonitor that looks back to the outbreak of SARS earlier this year. Industry mounted a quick response to this threat, and again there are instances of public bodies providing support to corporate efforts. The outbreak was effectively managed by isolation and containment to prevent its spread, and this highlights how important diagnosis of disease can be. A valuable immediate contribution of industry has been the development of a diagnostic allowing differentiation of SARS infected patients from those with other viral diseases such as flu - this can quickly contribute to the isolation and containment effort.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
 |
